ProstaLund (Sweden) Performance
| PLUN Stock | SEK 9.00 2.00 28.57% |
The company holds a Beta of -0.91, which implies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning ProstaLund are expected to decrease slowly. On the other hand, during market turmoil, ProstaLund is expected to outperform it slightly. At this point, ProstaLund AB has a negative expected return of -0.79%. Please make sure to check ProstaLund's maximum drawdown, potential upside, kurtosis, as well as the relationship between the value at risk and skewness , to decide if ProstaLund AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days ProstaLund AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 10.5 M | |
| Free Cash Flow | -15 M |
ProstaLund |
ProstaLund Relative Risk vs. Return Landscape
If you would invest 1,596 in ProstaLund AB on September 28, 2024 and sell it today you would lose (696.00) from holding ProstaLund AB or give up 43.61% of portfolio value over 90 days. ProstaLund AB is generating negative expected returns and assumes 5.2609% volatility on return distribution over the 90 days horizon. Simply put, 46% of stocks are less volatile than ProstaLund, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
ProstaLund Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ProstaLund's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ProstaLund AB, and traders can use it to determine the average amount a ProstaLund's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1497
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PLUN |
Estimated Market Risk
| 5.26 actual daily | 46 54% of assets are more volatile |
Expected Return
| -0.79 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ProstaLund is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ProstaLund by adding ProstaLund to a well-diversified portfolio.
ProstaLund Fundamentals Growth
ProstaLund Stock prices reflect investors' perceptions of the future prospects and financial health of ProstaLund, and ProstaLund fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ProstaLund Stock performance.
| Return On Equity | -0.25 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.61) % | |||
| Operating Margin | (0.59) % | |||
| Current Valuation | 215.81 M | |||
| Shares Outstanding | 57.19 M | |||
| Price To Book | 5.09 X | |||
| Price To Sales | 13.54 X | |||
| Revenue | 17.07 M | |||
| EBITDA | (7.54 M) | |||
| Cash And Equivalents | 19.11 M | |||
| Cash Per Share | 2.98 X | |||
| Book Value Per Share | 0.79 X | |||
| Cash Flow From Operations | (5.8 M) | |||
| Earnings Per Share | (0.17) X | |||
| Total Asset | 43.48 M | |||
| Retained Earnings | 19 M | |||
| Current Asset | 27 M | |||
| Current Liabilities | 4 M | |||
About ProstaLund Performance
Assessing ProstaLund's fundamental ratios provides investors with valuable insights into ProstaLund's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ProstaLund is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
ProstaLund AB develops, manufactures, and sells urological devices and treatments.Things to note about ProstaLund AB performance evaluation
Checking the ongoing alerts about ProstaLund for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ProstaLund AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ProstaLund AB generated a negative expected return over the last 90 days | |
| ProstaLund AB has high historical volatility and very poor performance | |
| ProstaLund AB has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 17.07 M. Net Loss for the year was (7.88 M) with profit before overhead, payroll, taxes, and interest of 14.68 M. | |
| ProstaLund AB has accumulated about 19.11 M in cash with (5.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.98. | |
| Roughly 51.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing ProstaLund's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ProstaLund's stock is overvalued or undervalued compared to its peers.
- Examining ProstaLund's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ProstaLund's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ProstaLund's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ProstaLund's stock. These opinions can provide insight into ProstaLund's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ProstaLund Stock Analysis
When running ProstaLund's price analysis, check to measure ProstaLund's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProstaLund is operating at the current time. Most of ProstaLund's value examination focuses on studying past and present price action to predict the probability of ProstaLund's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProstaLund's price. Additionally, you may evaluate how the addition of ProstaLund to your portfolios can decrease your overall portfolio volatility.